Holen Sie sich die Stockscreener-App
15.50
0.06%
0.010
Handel nachbörslich:
15.50
Schlusskurs vom Vortag:
$15.49
Offen:
$15.53
24-Stunden-Volumen:
617.69K
Relative Volume:
0.99
Marktkapitalisierung:
$1.09B
Einnahmen:
$1.23M
Nettoeinkommen (Verlust:
$-214.90M
KGV:
-3.7601
EPS:
-4.1222
Netto-Cashflow:
$-151.25M
1W Leistung:
-1.40%
1M Leistung:
+0.65%
6M Leistung:
-35.01%
1J Leistung:
-34.85%
1-Tages-Spanne:
$15.26
$16.61
1-Wochen-Bereich:
$14.00
$17.29
52-Wochen-Spanne:
$10.91
$40.26
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Firmenname
Spyre Therapeutics Inc
Sektor
Branche
Telefon
(617) 651-5940
Adresse
221 CRESCENT STREET, WALTHAM
Vergleichen Sie SYRE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
15.50 | 1.09B | 1.23M | -214.90M | -151.25M | -4.1222 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-08 | Eingeleitet | Leerink Partners | Outperform |
| 2025-03-18 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-04 | Eingeleitet | Wedbush | Outperform |
| 2024-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-05-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-03-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-12-11 | Eingeleitet | Guggenheim | Buy |
| 2023-12-11 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2019-03-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-09-04 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-14 | Bestätigt | Needham | Buy |
Alle ansehen
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward (SYRE) - Seeking Alpha
Spyre reports results from early stage TL1A antibody trials (SYRE) - Seeking Alpha
Transcript : Spyre Therapeutics, Inc.Special Call - MarketScreener
Spyre Therapeutics Announces Positive Interim Phase 1 Results fo - GuruFocus
Spyre Therapeutics Says Anti-TL1A Antibodies Met Objectives in Interim Phase 1 Study - MarketScreener
Spyre Therapeutics Announces Positive Phase 1 Results - TipRanks
Spyre Therapeutics (SYRE) Advances Clinical Trials with Encouraging Interim Results | SYRE Stock News - GuruFocus
Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts - PR Newswire
Spyre Therapeutics to Host Conference Call and Webcast to Report - GuruFocus
Spyre Therapeutics to Unveil First Human Trial Data for Revolutionary IBD Antibody Treatment - Stock Titan
Bank of America Corp DE Reduces Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
California State Teachers Retirement System Grows Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 22,540 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Transcript : Spyre Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09 - MarketScreener
Spyre Therapeutics Announces Grants of Inducement Awards | SYRE Stock News - GuruFocus
Spyre Therapeutics Expands Team with Strategic Stock Options Worth $773K to Three Key Hires - Stock Titan
Squarepoint Ops LLC Purchases 6,754 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Transcript : Spyre Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 08 - marketscreener.com
Guggenheim reiterates Buy rating on Spyre stock citing pipeline progress By Investing.com - Investing.com Canada
Spyre Therapeutics Announces Grants of Inducement Awards - PR Newswire
Spyre Therapeutics to Participate in Upcoming June Investor Conferences - Eastern Progress
Wall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should Know - sharewise
Millennium Management LLC Acquires Shares of 167,804 Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Grows Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics to Participate in Upcoming June Investor Conf - GuruFocus
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Recommendation of “Buy” by Analysts - Defense World
Spyre Therapeutics to Participate in Upcoming June Investor Conferences | SYRE Stock News - GuruFocus
Spyre Therapeutics IBD Pipeline Updates Coming at Major June Healthcare Conferences - Stock Titan
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Purchased by Deutsche Bank AG - Defense World
BNP Paribas Financial Markets Takes $437,000 Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Northern Trust Corp - Defense World
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by The Manufacturers Life Insurance Company - Defense World
How Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34% - Yahoo Finance
First Trust Advisors LP Invests $548,000 in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Shares Up 12.6% on Earnings Beat - Defense World
Spyre Therapeutics: Q1 Earnings Snapshot - New Haven Register
Spyre Therapeutics Reports Q1 2025 Financial Results - TipRanks
Spyre (SYRE) Advances Clinical Trials with Strong Financial Backing | SYRE Stock News - GuruFocus
Spyre Therapeutics Inc Reports Q1 2025 EPS of -$0.60, Beating Estimates, Amid $44.8 Million Net Loss - GuruFocus
Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Stock Position Boosted by Tower Research Capital LLC TRC - The AM Reporter
MetLife Investment Management LLC Has $498,000 Stock Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - The AM Reporter
Spyre Therapeutics (NASDAQ:SYRE) Given Outperform Rating at Wedbush - Defense World
Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $49.57 - Defense World
Spyre Presents Promising SPY001 IBD Data And Combination Therapy Results At DDW 2025 - Nasdaq
Spyre Therapeutics (SYRE) Showcases Promising IBD Treatment Data at Upcoming Conference | SYRE Stock News - GuruFocus
Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001 | SYRE Stock News - GuruFocus
Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001 - PR Newswire
Invesco Ltd. Sells 118,195 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Wells Fargo & Company MN Purchases 6,908 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics Awards 64,400 Shares in Stock Options to Strategic New Employee Hires - Stock Titan
Finanzdaten der Spyre Therapeutics Inc-Aktie (SYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Spyre Therapeutics Inc-Aktie (SYRE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Albers Jeffrey W. | Director |
Oct 25 '24 |
Sale |
36.43 |
300 |
10,929 |
34,060 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):